MELBOURNE, Australia, Feb. 21, 2024 Immuron Limited , an Australian based and globally integrated biopharmaceutical company is pleased to advise our Research & Development Manager, Joanne Casey,.
Highlights: Travelan® sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 millionAustralian Travelan® YTD Jan 2024 sales $2.1 millionUSA Travelan® YTD Jan 2024 sales $0.6.
MELBOURNE, Australia, Feb. 08, 2024 Immuron Limited , an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore.
Highlights: Record half yearly Travelan® sales of $2,334,969Total sales of A$2,355,580 in H1, FY24 $1,771,932 increase on H1, FY23 sales51% higher than pre-pandemic period H1, FY20 sales .
Highlights: US Naval Medical Research Command campylobacter clinical program completes in-patient phase Manufacture of IMM-529 drug substance to support the Pre-IND information package has been.